ImpediMed Secures US$15 million Growth Capital to Drive Expansion

ImpediMed Limited (ASX: IPD) has secured a US$15 million growth capital facility through its subsidiary, ImpediMed, Inc., with SWK Funding LLC, a healthcare-focused finance firm. The five-year facility provides financial flexibility to support business expansion and commercialization efforts.

Board Chair Christine Emmanuel-Donnelly emphasized the importance of strategic investment while preserving shareholder value, ensuring a strong financial base for long-term growth. Managing Director Dr. Parmjot Bains highlighted the confidence shown by SWK Holdings in ImpediMed’s SOZO digital health platform, reinforcing its commercial potential.

The agreement includes an initial US$10 million tranche, with an additional US$5 million available upon meeting FY25 sales targets. The funding enhances ImpediMed’s ability to capitalize on business opportunities and drive future profitability.

ImpediMed remains committed to advancing its innovative bioimpedance spectroscopy (BIS) technology, improving patient outcomes in lymphoedema, heart failure, and malnutrition management worldwide.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com